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Over the past years, echocardiography has been
shown to play a crucial role in the accurate evaluation
of left ventricular function particularly in patients
suspected for ischemic heart disease [1–3]. The ability
to rapidly perform bedside echocardiography with
Echo-Doppler imaging places this modality in the
heart of clinical research to understand cardiac
function and to quantify various associated abnor-
malities [4–8]. Echocardiography has found a major
niche in visualizing left ventricular function both at
rest and during stress. Widespread use of dobutamine-
echocardiography has contributed to more frequent
recognition of wall motion disturbances due to
coronary artery disease [9–11]. Its applicability in
prognostic assessment of such patients has been
repeatedly conﬁrmed, particularly in diabetic subjects
[12]. Coronary artery disease is the leading cause of
morbidity and mortality in patients with diabetes
mellitus. In fact, patients with diabetes have the same
risk of myocardial infarction as do non-diabetic
subjects with a history of infarction. Present data
indicate a substantially elevated risk of cardiovascular
disease even before a clinical diagnosis of type-2
diabetes has been made. Identifying patients with
diabetes suspected for coronary artery disease who
will beneﬁt from medical and/or invasive intervention
to prevent cardiovascular events is a challenge in both
symptomatic and asymptomatic patients. The decision
to evaluate patients with diabetes who are asymptom-
atic for coronary artery disease presents the greatest
challenge; investigation will reveal 10–15% of these
patients to have coronary artery disease. Current
diagnostic tools include exercise tolerance testing
[13–18], stress myocardial perfusion imaging
[19–26], stress MRI [27–57], and stress echocardiog-
raphy [12].
In the current issue of the International Journal of
Cardiovascular Imaging, Innocenti et al. [58] studied
322 type-2 diabetic patients who underwent dobuta-
mine-stress echocardiography for known or suspected
coronary artery disease. Indications to dobutamine-
stress echocardiography were evaluation of symp-
toms suggesting presence of coronary artery disease
or assessment of known coronary artery disease. End-
points of the study were all-cause mortality, cardiac
death, and non-fatal myocardial infarction. During
dobutamine-stress echocardiography, viability and
inducible ischemia developed in 65 (20%) and 192
(60%) subjects, respectively. Severe ischemia
(deﬁned as an asynergic area including more than
40% of all segments combined with a rate pressure
product \17000) appeared in 88 (27%) of patients.
Presence of diabetic treatment or microvascular
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longer diabetes duration was associated with higher
all-cause mortality at univariate analysis. At multi-
variate analysis, advanced age, decreased left ven-
tricular ejection fraction, and peripheral vascular
disease independently determined increased all-cause
mortality. New hard cardiac events occurred more
frequently in presence of peripheral vascular disease,
viability and severe ischemia. The authors concluded
that in diabetic patients with known or suspected
coronary artery disease, presence of viability and
severe ischemia during dobutamine-stress echocardi-
ography are independently associated with a higher
occurrence of hard cardiac events. The clinical
variables showed a weak prognostic role, except for
age and presence of peripheral vascular disease.
These ﬁndings emphasize the role of stress echocar-
diography in patients with type-2 diabetes.
It should, however, be realized, that the value of
stress imaging in diabetic patients is dependent on the
presence and nature of symptoms. In symptomatic
patients, myocardial perfusion imaging provides
similar diagnostic and prognostic accuracies as in
patients without diabetes [59]. However, the utility of
screening patients with type-2 diabetes for asymp-
tomatic coronary artery disease remains controversial
[60–62]. For instance, the Detection of Ischemia in
Asymptomatic Diabetics (DIAD) study [62] assessed
whether routine screening for coronary artery disease
identiﬁed patients with type-2 diabetes as being at
high cardiac risk and whether it affects their cardiac
outcomes. A total of 1123 participants with type-2
diabetes and no symptoms of coronary artery disease
were randomly assigned to be screened with adeno-
sine-stress radionuclide myocardial perfusion imag-
ing or no screening. It was found that in patients with
diabetes, the cardiac event rates were low and were
not signiﬁcantly reduced by screening for myocardial
ischemia over almost 5 years. Therefore, ﬁndings
from the DIAD study indicate that routine screening
of asymptomatic patients with diabetes is not
justiﬁed.
Notwithstanding, the current study [58] shows that
dobutamine-stress echocardiography has a major role
in the evaluation of diabetic patients. In symptomatic
diabetic patients with known or suspected coronary
artery disease, advanced age and reduced left ven-
tricular function are independent predictors of total
mortality. Presence of viability and severe ischemia
during dobutamine-stress echocardiography are inde-
pendently associated with higher occurrence of new
major cardiac events. Therefore, dobutamine-stress
echocardiography is an important prognostic imaging
modality in assessing cardiovascular risk in symp-
tomatic diabetic patients.
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